Insulin

The Arkansas attorney general on May 11 accused drugmakers and pharmacy benefit managers of colluding to drive up the price of insulin drugs, the latest in a series of lawsuits to take aim at skyrocketing costs for the life-sustaining medicine.

Cigna Corp. raised the health insurer’s annual adjusted profit forecast on May 6, following a decline in COVID-related costs and no sign of pent-up demand for medical procedures that were delayed due to the pandemic.

Cigna

Cigna Corp. said on Aug. 26 the company would now sell health insurance plans on online marketplaces created by the Affordable Care Act (ACA), popularly known as Obamacare, in three new U.S. states and 93 new counties.

The U.S. Food and Drug Administration approved Biogen’s aducanumab, the first drug to target an underlying cause of Alzheimer’s disease. The drug, to be sold under the brand Aduhelm, is the first new approval of an Alzheimer’s drug since 2003 and the only treatment designed to slow progression of the mind-robbing disease.

Cigna Corp. agreed to sell the health insurer’s disability and accidental death insurance unit for company employees to New York Life Insurance Co. in a $6.3 billion deal.

McCann Worldgroup has partnered with Cigna International Markets in their latest initiative, which is helping the world see stress differently.

Cigna introduced a plan to fully cover costs for expensive gene therapies, eliminating any out-of-pocket payments for customers.

The Trump administration scrapped a proposal for lowering prescription medicine prices, backing down from a policy that would have required health insurers to pass on billions of dollars in rebates they receive from drugmakers to Medicare patients.

Eli Lilly and Co. pulled ahead in a three-way race with Amgen Inc. and Teva Pharmaceutical Industries Ltd. in attracting new patients to a new class of migraine drugs, and seeks to build on that advantage by stressing that the company’s therapy can completely prevent headaches in a small percentage of patients.

Health insurer Cigna Corp. launched a program aimed at ensuring some diabetes patients pay no more than $25 for a 30-day supply of insulin in the wake of heightened public scrutiny over soaring prices of the life-saving drug.